Many of the diseases commonly encountered in clinical practice may be considered as "recurrent", there being episodes of disease activity followed by variable periods of quiescence or low-grade activity. Although the aetiology of many of these conditions is unknown (for example, rheumatoid arthritis, ulcerative colitis, multiple sclerosis), certain infectious diseases are well known for their ability to recur. Interestingly, the genital tract appears particularly prone to recurrent disease. For example, true recurrence rather than reinfection has been well documented for herpes simplex virus (HSV) and human papillomavirus infection, candidiasis and nongonococcal urethritis. For the majority of patients recurrences are infrequent and pose few problems. However, a significant minority suffer frequent recurrences and experience severe physical and psychological morbidity. This article reviews various studies which have attempted to examine the immunopathogenesis of recurrent genital tract infection or which have suggested possible mechanisms to account for disease recurrence. Before detailing the various infections, however, it is important to note that the immune mechanisms operating at mucosal sites are somewhat different from those providing systemic immunity. Mucosal antibody secretion involves a complex system in which IgA predominates. The IgA in genital secretions (secretory IgA) is different from the IgA found in serum and is composed of a 10-S dimer, J chain, and a secretory component. A proportion of patients with genital warts have lesions which are either resistant to treatment or frequently recur following treatment. A small number of studies have suggested that impaired cell mediated immunity may be responsible. Seski et al reported that women with recalcitrant genital warts and vulval intraepithelial neoplasia produced abnormal lymphocyte transformation responses to several mitogens.394" Impaired delayed hypersensitivity, assessed by leucocyte migration inhibition and tuberculin and dinitrochlorobenzene skin tests, has also been reported in patients with genital warts of long duration.4' A study of patients with "genital neoplasia-papilloma syndrome" (HPV-associated lesions in multiple genital sites with at least one intraepithelial or invasive squamous neoplasia) has documented decreased lymphocyte proliferative responses to mitogens and 374 increased suppressor-cytotoxic T-cells (CD8 +) compared with control subjects.42 Interestingly, over 50% of the patients studied had a history of recurrent candida infections. Immunosuppressed patients with defective cell mediated immunity are particularly prone to develop multiple intractable genital warts,43 again emphasising the importance ofthe cell mediated immune response. 
Conclusion
The genital infections discussed in this article all share the ability to produce frequent recurrences in certain individuals. Examining the immunological mechanisms underlying these recurrences reveals cellmediated immunosuppression as a common feature. This immunosuppression may be antigen specific or non-specific and involves activated suppressor cells and/or the production of soluble inhibitory factors. Suppressor systems are known to regulate the immune responses to a variety of infectious agents"'55 and are the subject of recent reviews."s5 A general feature of the suppressor T-cell system is the involvement of major histocompatibility complex genes in the induction and expression of suppressor T-cell activity. A relationship has been documented between HLA-B15 antigen and low in-vitro and in-vivo responsiveness to candida antigen58 and between HLA-A1 and recurrent circumoral herpes infection.5 Information regarding the HLA status ofpatients with recurrent genital tract infection is lacking. Further work is required to elucidate fully the role of suppressor cells and their products in the pathogenesis of recurrent genital tract infection in humans. This is of some importance since they could provide a target for treatment aimed at breaking the disease cycle. In addition, the reports of prostaglandin E2 induced immunosuppression and the abrogation of antigen-specific suppression of mononuclear cell proliferation by prostaglandin Sonnex inhibitors may also provide a basis for therapy. Preliminary results suggest that some women with recurrent candidiasis benefit from taking ibuprofen.3 Although this particular medication had no effect in treating clinical recurrences of genital herpes' the use ofibuprofen, or a similar drug, as a prophylactic agent has not been assessed.
There are obviously many avenues along which future research could proceed. Our knowledge oflocal immunity within the genital tract is slowly growing and the concept of "genital tract associated lymphoid tissues", comparable to the skin and gut-associated lymphoid tissues, may soon be appreciated. The role of suppression of local immunity (for example, IgA responses), as suggested by Nash,6" is one particular area which merits investigation. An improved understanding of the immunopathogenesis of recurrent genital tract infection will hopefully enable us to manage these debilitating conditions rather more effectively.
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